On Friday, President Trump introduced 4 govt orders directed at lowering prescription drug costs by ordering sure actions by the Division of Well being and Human Companies (“HHS”). One order – which has obtained probably the most damaging response from the pharmaceutical business – would create a “most-favored nation” coverage to restrict the value Medicare Half B pays for sure medicine to the bottom worth paid in one other Group for Financial Cooperation and Growth nation. The White Home didn’t launch the textual content of this order on Friday and said that it could not take impact till August 24, or in any respect if pharmaceutical corporations can supply an alternate proposal to considerably scale back drug costs or if Congress acts.
One other of the chief orders would require HHS to exclude from federal Anti-Kickback Statute (“AKS”) protected harbor safety rebates supplied by drug producers to pharmacy profit managers (“PBMs”), well being plans, and pharmacies however not handed on to sufferers. As an alternative, HHS could be required to create new protected harbors to permit plans, pharmacies, and PBMs to use reductions to cut back sufferers’ out-of-pocket prices, in addition to enable for bona fide PBM service charges. Nevertheless, the order supplies that earlier than taking these actions, HHS should affirm that they’d not improve Federal spending, Medicare beneficiary premiums, or affected person out-of-pocket prices. Additional, the regulatory revisions demanded by the order might be topic to authorized problem, each as an illegitimate try to slim the AKS’s statutory low cost exception and a violation of Medicare Half D’s non-interference clause.
A 3rd govt order would require Federally Certified Well being Facilities (“FQHCs”) to cross on reductions on insulin and injectable epinephrine obtained by the 340B Prescription Drug Program to sure sufferers. FQHCs could at present get hold of medicine at 340B discounted costs, then promote the medicine to sufferers at a better worth, subsidizing their typically very low margin operations. The chief order requires HHS – “to the extent permitted by legislation” – to take motion to make continued 340B participation contingent on offering these medicine on the worth paid by the FQHC to low revenue sufferers who (1) have a excessive price sharing requirement for both insulin or injectable epinephrine, (2) have a excessive unmet deductible, or (3) don’t have any insurance coverage. The order doesn’t apply to hospitals taking part within the 340B program.
Lastly, a fourth govt order directs HHS – “as applicable and in keeping with relevant legislation” – to finalize a rule permitting for importation of sure pharmaceuticals from Canada and to facilitate waivers of the prohibition on importation of pharmaceuticals usually, in addition to to authorize the re-importation of insulin merchandise as needed for emergency medical care.
Copyright © 2020, Sheppard Mullin Richter & Hampton LLP.Nationwide Legislation Assessment, Quantity X, Quantity 209